IPERION LIMITED

CONDENSED INTERIM FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

Dear Shareholders

The Directors of Iperion Limited, ("the Company") are pleased to report its financial results for the six months ended 30 September 2024.

Financial Results

Iperion reports an unaudited net loss attributable to shareholders of \$363,730 for the half year ended 30 September 2024. This compares with a net loss attributable to shareholders of \$462,614 for the same period last year.

There was no sales income in the period. The improvement in result compared to the same period last year is mainly related to the establishment of the outsourced pilot manufacturing plant that increased costs by \$100,000 in the previous year.

Compared to the prior period, administrative expenses incurred in the half year ended September 2024 decreased by \$14,715.

Operations and Product Development

Work is ongoing internationally to build awareness of Pathoglaze through direct contact with potential users and through business trade exhibitions.

A number of potential users are currently conducting their own trials to identify the correct Pathoglaze mix to suit their particular requirements. Ongoing Research and Development by Iperion's outsourced manufacturing provider continues to expand the range of applications for Pathoglaze and the potential size of the market for the product.

The Company will provide the market with any updates as to material developments in due course.

The Directors of Iperion extend their thanks to the shareholders for their support of the Company.

CONTENTS

STATEMENT OF COMPREHENSIVE INCOME	3
STATEMENT OF FINANCIAL POSITION	4
STATEMENT OF CHANGES IN EQUITY	5
STATEMENT OF CASH FLOWS	6
NOTES TO THE FINANCIAL STATEMENTS	7
BUSINESS DIRECTORY	10

STATEMENT OF COMPREHENSIVE INCOME

For the period ended 30 September 2024

	Unaudited	Unaudited
	Six months	Six months
	Sep-24	Sep-23
	\$	\$
Outsourced manufacturing plant expenses	(200,000)	(300,000)
Interest Income	8,123	20,790
Administrative expenses	(168,689)	(183,404)
Loss before income tax	(363,730)	(462,614)
Income tax expense	-	-
Net loss for the period attributable to shareholders	(363,730)	(462,614)
Other comprehensive income	-	-
Total comprehensive loss for the period, net of tax, attributable to shareholders	(363,730)	(462,614)
Earnings per share:	cents	cents
Basic and diluted earnings/(loss) per share	(0.071)	(0.090)

STATEMENT OF FINANCIAL POSITION

As at 30 September 2024

	Unaudited	Audited
	Six months	Year
	Sep-24	Mar-24
	\$	\$
Assets		
Current assets		
Cash and cash equivalents	86,796	168,647
Term Deposit	501,721	691,074
Interest accrued on term deposits	75	6,760
GST receivable	7,379	-
Income tax receivable (RWT)	4,140	12,030
	600,111	878,511
Non-current assets		
NZX Deposit	20,000	20,000
	20,000	20,000
Total assets	620,111	898,511
Equity and liabilities		
Current liabilities		
Trade and other payables	179,761	93,105
GST Payable	-	1,325
	179,761	94,430
Non-current liabilities		
Total liabilities	170 764	04 420
Total habilities	179,761	94,430
Fauity		
Equity Issued capital	5,672,856	5,672,856
Accumulated loss	(5,232,506)	(4,868,775)
Total equity	(5,232,506) 440,350	<u>(4,868,775)</u> 804,081
	440,350	004,081
Total equity and liabilities	620,111	898,511

28 November 2024

/illins

Director: Bruce Dunlop

Director: John Cilliers

STATEMENT OF CHANGES IN EQUITY

For the period ended 30 September 2024

	lssued capital	Accumulated Loss	Total equity
	\$	\$	\$
As at 1 April 2023	5,672,856	(4,046,516)	1,626,340
Loss for the period	-	(462,615)	(462,615)
Total comprehensive loss	-	(462,615)	(462,615)
Unaudited balance for the period ended 30 September 2022	5,672,856	(4,509,131)	1,163,725
As at 1 October 2023	5,672,856	(4,509,131)	1,163,725
Loss for the period	-	(359,644)	(359,644)
Total comprehensive loss	-	(359,644)	(359,644)
At 31 March 2024	5,672,856	(4,868,775)	804,081
As at 1 April 2024	5,672,856	(4,868,775)	804,081
Loss for the period		(363,731)	(363,731)
Total comprehensive loss	-	(363,731)	(363,731)
Unaudited balance for the period ended 30 September 2024	5,672,856	(5,232,506)	440,350

STATEMENT OF CASH FLOWS

For the period ended 30 September 2024

	Unaudited	Unaudited
	Six months	Six months
	Sep-24	Sep-23
	\$	\$
Operating activities		
Interest received	14,808	15,124
Payments to suppliers	(294,836)	(407,381)
Net GST refunds received	4,098	19,937
Income tax paid	(4,140)	(4,233)
Income tax refund received	12,030	5,766
Net cash flows from operating activities	(268,040)	(370,787)
Investing activities		
Purchase of intangible assets	(3,164)	-
Cash received from/(invested in) maturity of term deposit	189,353	(10,885)
Net cash flows from investing activities	186,189	(10,885)
Net decrease in cash and cash equivalents	(81,851)	(381,672)
Cash and cash equivalents at beginning of year	168,647	382,113
Cash and cash equivalents at end of year	86,796	441

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF ACCOUNTING POLICIES

Reporting entity

These unaudited interim financial statements and notes represent those of Iperion Limited ("IPR" or "the Company").

Iperion Limited is a limited liability company incorporated and domiciled in New Zealand. The registered office and principal place of business are disclosed in the directory to the annual report.

There are no seasonal or cyclical influences on these interim results.

Basis of preparation

These unaudited interim financial statements for the six months ended 30 September 2024 have been prepared in accordance New Zealand Generally Accepted Accounting Practice ("NZ GAAP"), with New Zealand Equivalent to International Accounting Standard 34: Interim Financial Reporting ("NZ IAS 34") and with International Accounting Standard 34: Interim Financial Reporting ("IAS 34").

Iperion Limited is a company registered under the Companies Act 1993 and is an FMC reporting entity under the Financial Markets Conduct Act 2013. The Company is listed on the NZX Market. These financial statements have been prepared in accordance with the requirements of the Financial Markets Conduct Act 2013 and the NZX Main Board Listing Rules.

The interim financial statements do not include all of the notes of the type normally included in an annual financial report. Accordingly, this report should be read in conjunction with the financial statements included in the annual report for the year ended 31 March 2024 which have been prepared in accordance with New Zealand equivalents to International Financial Reporting Standards ("NZ IFRS") and International Financial Reporting Standards ("IFRS").

The interim financial statements are presented in New Zealand dollars which is the Company's functional and presentation currency and are rounded to the nearest dollar.

The interim financial statements are unaudited. The comparative information as at 31 March 2024 is audited.

Accounting policies

The interim financial statements have been prepared using the same accounting policies and methods of computation detailed in the audited financial statements for the year ended 31 March 2024. For details of the accounting policies please refer to the 2024 Annual Report.

These unaudited interim financial statements have been approved for issue by the Board of Directors on 28 November 2024.

2. SEGMENT INFORMATION

There have been no material change in the nature of operating segments since 31 March 2024.

3. ADMINISTRATIVE EXPENSES

	Unaudited	Unaudited
	Six months	Six months
	Sep-24	Sep-23
	\$	\$
Fees paid to BDO Auckland* - statutory audit	25,000	20,000
Fees paid to BDO Auckland* - statutory audit prior year	14,190	13,150
Contractors	24,095	28,010
Directors' fees	78,000	78,000
Travel and accommodation	7,130	15,536
Legal Fees	890	5,920
NZX Listing and registry costs	17,054	19,518
Other	2,330	3,270
	168,689	183,404

4. FINANCIAL RISK MANAGEMENT

There have been no material changes in the management of risk or in any risk management policies in the current period.

5. EARNINGS PER SHARE

		Unaudited	Unaudited
		Six months	Six months
		Sep-24	Sep-23
Total comprehensive loss for the period, net of tax, attributable to shareholders	[\$]	(\$363,730)	(\$462,614)
Weighted average number of shares		514,894,500	514,894,500
Basic and diluted earnings/(loss) per share	[cents]	(0.071)	(0.090)

There have been no changes in the estimated useful life of key items of plant and equipment.

6. NET TANGIBLE ASSET BACKING

		Unaudited	Audited
		Sep-24	Mar-24
Total Assets		620,111	898,511
Less:			
Total Liabilities		(179,761)	(94,430)
Net Tangible Assets	[\$]	440,350	804,081
Issued shares at balance date		514,894,500	514,894,500
Net Tangible Asset per share (cents)	[cents]	0.086	0.156

7. RELATED PARTY TRANSACTIONS

Related party transactions for the period consisted of:

- Director fees of \$18,000 each for KC Ng, Bruce Dunlop and John Cilliers and \$24,000 for the chairman Chang Ku EE.
- Included in administrative expenses is Management fees of \$18,000 paid to Chang Ku EE and KC Ng and \$6,095 was paid to John Cilliers in relation to accounting services and preparation of the 2024 annual report.

8. COMMITMENTS AND CONTINGENT LIABILITIES

The antimicrobial license agreement contains minimum performance targets that set minimum royalty of 2.1% to be paid on revenue of SGD \$150,000 by 30 September 2025 and 2.1% on revenue of SGD \$1m annually from 30 September 2026. The maximum contingent liability arising in the event that no revenue has been earned by 30 September 2025 is approximately \$3,780 and \$25,200 on 30 September 2026.

In accordance with the terms of the Pilot Outsourcing Agreement entered on 20 January 2023 for the commercialization of antimicrobial coatings, the Company will pay fixed fees of NZD\$400,000 per annum towards the setup of the facility, engagement of core personnel and subsequent services, as well as commission of 30% on gross profit. Invoices under the Pilot Outsourcing Agreement are payable in 30-day instalments. However, the Company has the ability to terminate the Pilot Outsourcing Agreement at any time, with prior notice to the Licensor, with no break fees.

There were no other capital commitments or contingent liabilities at 30 September 2024 (31 March 2024: \$nil).

9. SIGNIFICANT EVENTS AFTER BALANCE DATE

There were no significant events subsequent to 30 September 2024.

10. AUDIT

These interim financial statements are not required to be audited.

BUSINESS DIRECTORY

Company number:	4844319
Directors:	Chang Ku EE, Chairman Kuan Chong NG Bruce Dunlop John Cilliers
Registered office:	Level 2 Tower Building, 50 Customhouse Quay, Wellington, 6011
Share Registrar	Link Market Services Limited Level 7, Zurich House 21 Queen Street Auckland 1010
Bankers:	Westpac Bank Limited
Solicitors:	Duncan Cotterill Wellington
Auditors:	BDO, Auckland Auckland